|
The latest Mainline newsletters for the General Public are listed here. |
For healthcare professionals we have a Mainline newsletter in a Professional version here. |
Mainline |
||
| Volume 2 | October 17, 2005 | Number 7 |
An Exclusive Continuing Education Publication of Acadiana Consultant Pharmacy Service |
||
Medication News & Update
On October 17, Eli Lilly and the Food and Drug Administration (FDA) notified health care professionals of a revision to the “Precautions” section of the prescribing information for duloxetine (Cymbalta). Postmarketing reports of hepatic injury (including hepatitis and cholestatic jaundice) suggest that patients with preexisting liver disease who take duloxetine may have an increased risk for further liver damage. The new labeling extends the precaution against using duloxetine in patients with substantial alcohol use to include those patients with chronic liver disease. It is recommended that duloxetine not be administered to patients with any hepatic insufficiency. For more information, visit http://www.fda.gov/medwatch/safety/2005/safety05.htm#Cymbalta
|
[ Home ]
[ About Us ]
[ Assessment Tools ]
[ Sample Consult ] |
